EUVIMEDEUVIMED entdecken
Fallbericht

Extreme variability in linezolid concentrations in the ICU: A case for routine therapeutic drug monitoring

Daniel Muñoz-Pichuante, María Ignacia Álvarez, Diego Reyes Hales, Lorenzo Villa Zapata

American Journal of Health-System Pharmacy · 2026

DOI: 10.1093/ajhp/zxaf235 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, 2026. Verfasst von Daniel Muñoz-Pichuante und 3 weiteren Autor:innen. Beteiligte Einrichtung: Escuela de Química y Farmacia, Facultad de Ciencias, Universidad San Sebastián, Valdivia, Chile. Hauptthemen laut MEDLINE: Linezolid, Drug Monitoring, Anti-Bacterial Agents, Gram-Positive Bacterial Infections. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Linezolid is an essential antimicrobial for treating multidrug-resistant gram-positive infections in critically ill patients. However, its pharmacokinetics (PK) are highly variable, potentially leading to subtherapeutic exposure or toxicity. Therapeutic drug monitoring (TDM) plays a critical role in guiding individualized dosing. Summary We describe a 66-year-old intensive care unit (ICU) patient treated with linezolid for vancomycin-resistant Enterococcus faecium (VRE) peritonitis and empyema. Despite standard dosing (600 mg IV every 12 hours), linezolid concentrations remained below the limit of quantification for 6 days, coinciding with persistent VRE isolation. A switch to continuous infusion (CI) at 2,400 mg/day achieved therapeutic levels (mean concentration [Cmean], 6.17 mg/L), but subsequent supratherapeutic exposure (Cmean, 12.12 mg/L; 24-hour area under the curve, 290.9 mg · h/L) led to adrenergic toxicity. Linezolid clearance declined from 14.6 to 6.2 L/h, unrelated to renal function, suggesting the influence of nonlinear elimination and alternate metabolic pathways. Following empyema drainage and ketamine withdrawal, PK parameters stabilized. This case highlights the extreme intraindividual PK variability of linezolid in critical illness. Contributing mechanisms may include ROS-driven CYP2J2 upregulation in acute lung injury, autoinhibition of metabolite formation, and drug interactions. CI enabled PK and pharmacodynamic target attainment when intermittent dosing failed but required TDM to avoid overexposure.

Conclusion

Routine TDM is essential to optimize the safely and effectively manage linezolid therapy in ICU patients. This case underscores the importance of integrating TDM with PK modeling to guide personalized dosing strategies in complex and dynamic clinical scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidDrug MonitoringAnti-Bacterial AgentsGram-Positive Bacterial InfectionsHumansAgedIntensive Care UnitsMaleEnterococcus faeciumVancomycin-Resistant Enterococci

Stichwörter der Autor:innen

critical illnessintensive care unitslinezolidpharmacodynamicspharmacokineticstherapeutic drug monitoring

Substanzen

LinezolidAnti-Bacterial Agents

Autor:innen und Institutionen

  • Escuela de Química y Farmacia, Facultad de Ciencias, Universidad San Sebastián, Valdivia, Chile.
  • Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA, USA.

Zitieren

APA

Muñoz-Pichuante, D., Álvarez, M. I., Reyes Hales, D., & Villa Zapata, L. (2026). Extreme variability in linezolid concentrations in the ICU: A case for routine therapeutic drug monitoring. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf235

Vancouver

Muñoz-Pichuante D, Álvarez MI, Reyes Hales D, Villa Zapata L. Extreme variability in linezolid concentrations in the ICU: A case for routine therapeutic drug monitoring. American Journal of Health-System Pharmacy. 2026. doi:10.1093/ajhp/zxaf235

BibTeX
@article{MuozPichuante2026,
  author = {Muñoz-Pichuante, Daniel and Álvarez, María Ignacia and Reyes Hales, Diego and Villa Zapata, Lorenzo},
  title = {Extreme variability in linezolid concentrations in the ICU: A case for routine therapeutic drug monitoring},
  journal = {American Journal of Health-System Pharmacy},
  year = {2026},
  doi = {10.1093/ajhp/zxaf235}
}
Kostenlos starten →